EDC for quality of life studies: QoL and PRO capture, eConsent, ePRO, and 21 CFR Part 11–aligned controls in one platform.
21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required
Validated QoL instruments have specific configuration requirements that your ePRO system must reproduce faithfully. The instrument developer specifies exact item wording, response option labels, scale anchors, recall periods (e.g., "in the past 7 days"), and presentation format. Deviating from these specifications can compromise the instrument’s psychometric properties and raise questions about measurement validity. Capture’s ePRO module supports the question types needed for standard QoL instruments: Likert scales for items like those in the EORTC QLQ-C30 or FACT-G, numeric rating scales for pain and symptom severity, slider-based visual analog scales for instruments using VAS, and single/multiple choice for categorical items. Study builders configure each item with the exact text, response options, and ordering specified by the instrument developer. For multi-domain instruments that include conditional sections (e.g., disease-specific modules that apply only to certain participants), skip logic ensures that only relevant sections are presented. This maintains the standardized administration while keeping the questionnaire burden appropriate for each participant.
When QoL is a primary or co-primary endpoint, the bar for data quality is at its highest. The FDA’s PRO Guidance (2009) and subsequent guidances on clinical outcome assessments establish that PRO/QoL instruments used as primary endpoints must have documented evidence of content validity, reliability, and ability to detect change. The data collection method must ensure that responses are contemporaneous (timestamped), not influenced by clinician assessments, and collected under standardized conditions. Capture supports these requirements through several mechanisms. Automatic timestamps on participant responses provide evidence of contemporaneous completion. Scheduling logic can be configured to ensure QoL assessments are completed before clinical visit procedures (avoiding assessment bias). The standardized digital presentation eliminates the variability that can occur with paper-based administration across sites. And the integrated audit trail provides complete documentation of when each assessment was completed, by whom, and under what instrument version. For studies submitted to regulatory agencies with QoL as a primary endpoint, this level of documentation and control strengthens the case for the endpoint’s reliability and the data’s integrity.
The analytical power of QoL studies comes from the ability to relate patient-reported quality-of-life data to clinical outcomes: does the treatment improve QoL alongside clinical measures? Does QoL deterioration predict clinical events? Is the QoL improvement clinically meaningful? Answering these questions requires a dataset where QoL and clinical data are co-located, aligned by participant and time point, and exported in a format ready for integrated analysis. Capture’s integrated platform produces exactly this kind of dataset. At export, QoL responses from ePRO and clinical data from CRFs are included in one structured file, linked by participant identifier and visit/time point. This eliminates the data merging step that is required when ePRO and EDC data come from separate systems—a step where alignment errors, missing links, and variable naming inconsistencies commonly occur. For analysis teams, this integrated export means they can proceed directly to QoL-specific analysis methods (mixed models for repeated measures, time-to-deterioration analysis, responder analysis using MCID thresholds) without first spending time on data preparation and reconciliation between separate source systems.
Overview
Quality of life (QoL) studies measure the impact of disease, treatment, or intervention on a participant’s overall well-being, functional status, and daily living. QoL endpoints are increasingly important in clinical research: regulatory agencies consider them in benefit-risk assessments, payers use them to evaluate treatment value, and clinicians rely on them to understand the patient experience beyond traditional clinical measures. Whether QoL is a primary endpoint or a key secondary outcome, the quality of its measurement depends directly on how QoL instruments are administered and data is captured. QoL studies typically combine clinician-assessed clinical data (disease severity, lab results, safety assessments) with patient-reported quality-of-life instruments (EQ-5D, SF-36, EORTC QLQ-C30, FACT-G, and disease-specific modules). This dual-data model requires an EDC system that handles both clinician CRFs and patient ePRO within one platform, with consistent data governance and a single audit trail. Capture provides EDC, eConsent, and ePRO in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. QoL instruments are configured using Capture’s ePRO module, which supports the question types needed for standard QoL assessments: Likert scales, numeric rating scales, visual analog scales (via slider), single and multiple choice, and free text. Participants complete QoL questionnaires on their own devices through a mobile-optimized web interface, and responses flow directly into the same dataset as clinician-entered CRF data. This integration means QoL study teams work from one system: one study build, one consent process, one dataset, and one audit trail. There is no separate QoL vendor to contract, validate, or reconcile data with.
QoL data has specific characteristics that affect EDC requirements. QoL instruments are standardized: validated questionnaires with specific item wording, response scales, recall periods, and scoring algorithms that must be reproduced exactly. Administration conditions matter: the instrument developer specifies whether the questionnaire should be completed before clinical assessments (to avoid influence), at specific time points, or in specific settings. And QoL data must be collected with the same data integrity and traceability as the clinical endpoints it accompanies. Standalone ePRO systems can capture QoL data, but they create a disconnect when that data needs to be analyzed alongside clinical CRF data. Separate systems mean separate audit trails, separate validation efforts, and a reconciliation step before analysis where data discrepancies can introduce errors or raise questions during regulatory review. For studies where QoL is a primary or co-primary endpoint, this fragmentation is a meaningful risk. Capture integrates QoL instrument administration with clinical data capture in one platform. Study builders configure QoL questionnaires alongside CRFs and consent forms. The same participant record contains consent documentation, clinical assessments, and QoL responses. This integration ensures that QoL data has the same provenance, audit trail, and governance as all other study data—which strengthens the integrity of the endpoint for regulatory and publication purposes.
FAQ
Explore the platform with a free sandbox. No sales call required.